Skip to main content

A Comparison of Sustained-release Bupropion and Placebo for Smokeless Tobacco Cessation

Buy Article:

$39.00 plus tax (Refund Policy)


Objective: To evaluate the potential efficacy of bupropion sustained release when used in combination with minimal counseling for moist snuff cessation in males. Methods: A double-blind, placebo-controlled 3-month trial. The active treatment group (n=35) received bupropion SR at 150 mg/qd day for the first 3 days, then beginning day 4 through day 49 (7 weeks) 150 mg/ b.i.d. The placebo group (n=35) received 1 tablet qd for 3 days and beginning day 4 through day 49, 1 tablet/b.i.d. Results: Bupropion 300 mg/day (150 b.i.d.) produced significantly higher quit rates for smokeless tobacco cessation at the end of treatment (7 weeks) than placebo (p=0.04) with an OR of 2.73. Conclusion: Bupropion SR appears to be effective for smokeless tobacco cessation.

Document Type: Research Article


Affiliations: 1: Addiction and Psychiatric Medicine Research, Department of Behavioral Medicine & Psychiatry, West Virginia University School of Medicine, Morgantown, WV. 2: Department of Community Medicine, West Virginia University School of Medicine, Morgantown, WV.

Publication date: September 1, 2002

More about this publication?
  • The American Journal of Health Behavior seeks to improve the quality of life through multidisciplinary health efforts in fostering a better understanding of the multidimensional nature of both individuals and social systems as they relate to health behaviors.

    The Journal aims to provide a comprehensive understanding of the impact of personal attributes, personality characteristics, behavior patterns, social structure, and processes on health maintenance, health restoration, and health improvement; to disseminate knowledge of holistic, multidisciplinary approaches to designing and implementing effective health programs; and to showcase health behavior analysis skills that have been proven to affect health improvement and recovery.

  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Review Board
  • Reprints and Permissions
  • ingentaconnect is not responsible for the content or availability of external websites

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more